HK1051691A1 - Hydroxylstilbenes and stilbene derivatives and analogues of anti-inflammatory and psoriasis treatment and protein kinase inhibition - Google Patents

Hydroxylstilbenes and stilbene derivatives and analogues of anti-inflammatory and psoriasis treatment and protein kinase inhibition

Info

Publication number
HK1051691A1
HK1051691A1 HK03104013A HK03104013A HK1051691A1 HK 1051691 A1 HK1051691 A1 HK 1051691A1 HK 03104013 A HK03104013 A HK 03104013A HK 03104013 A HK03104013 A HK 03104013A HK 1051691 A1 HK1051691 A1 HK 1051691A1
Authority
HK
Hong Kong
Prior art keywords
analogues
inflammatory
hydroxylstilbenes
protein kinase
kinase inhibition
Prior art date
Application number
HK03104013A
Other languages
English (en)
Inventor
Genhui Chen
John M Webster
Jianxiong Li
Kaiji Hu
Jiang Zhu
Original Assignee
Celestial Pharmaceuticals Shen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celestial Pharmaceuticals Shen filed Critical Celestial Pharmaceuticals Shen
Publication of HK1051691A1 publication Critical patent/HK1051691A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK03104013A 1999-12-06 2003-06-06 Hydroxylstilbenes and stilbene derivatives and analogues of anti-inflammatory and psoriasis treatment and protein kinase inhibition HK1051691A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16875899P 1999-12-06 1999-12-06
US17330099P 1999-12-28 1999-12-28
PCT/CA2000/001433 WO2001042231A2 (en) 1999-12-06 2000-12-06 Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1051691A1 true HK1051691A1 (en) 2003-08-15

Family

ID=26864425

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104013A HK1051691A1 (en) 1999-12-06 2003-06-06 Hydroxylstilbenes and stilbene derivatives and analogues of anti-inflammatory and psoriasis treatment and protein kinase inhibition

Country Status (11)

Country Link
US (1) US20030171429A1 (xx)
EP (1) EP1248774B1 (xx)
JP (1) JP4880847B2 (xx)
KR (1) KR100805907B1 (xx)
CN (1) CN1319959C (xx)
AT (1) ATE444960T1 (xx)
CA (1) CA2393297C (xx)
DE (1) DE60043120D1 (xx)
ES (1) ES2334635T3 (xx)
HK (1) HK1051691A1 (xx)
WO (1) WO2001042231A2 (xx)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031117A1 (en) * 2000-10-06 2004-04-15 Welichem Biotech Inc. Novel bioactive diphenyl ethene compounds and their therapeutic applications
US7321050B2 (en) 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
US6552085B2 (en) 2000-08-16 2003-04-22 Insmed Incorporated Compositions containing hypoglycemically active stilbenoids
US6410596B1 (en) * 2000-08-16 2002-06-25 Insmed Incorporated Compositions containing hypoglycemically active stillbenoids
US20040102517A1 (en) * 2001-01-18 2004-05-27 Genhui Chen Novel1,2-diphenylethene derivatives for treatment of immune diseases
MXPA04000695A (es) * 2001-07-23 2005-08-26 Galileo Pharmaceuticals Inc Compuestos citoprotectores, formulaciones farmaceuticas y cosmeticas y metodos.
US7384920B2 (en) 2001-07-26 2008-06-10 Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla Use of stilbene compounds in the manufacture of medicament for the prevention and treatment of diabetes or retrovirus-associated diseases
FR2830860A1 (fr) * 2001-10-12 2003-04-18 Univ Pasteur Procede de synthese du (z)-3, 5, 4'-trimethoxystilbene, compose obtenu et utilisations dudit compose, notamment comme medicament, en particulier comme anticancereux
EP2060255B1 (en) * 2001-11-02 2013-06-05 The Regents of the University of California Compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
US20060293256A1 (en) * 2002-08-06 2006-12-28 Masateru Yamada Remedy or preventive for kidney disease and method of diagnosing kidney disease
US20050080021A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
WO2004024895A2 (en) * 2002-09-16 2004-03-25 Plexxikon, Inc. Crystal structure of pim-1 kinase
GB2411353A (en) * 2004-02-25 2005-08-31 Univ Hertfordshire Resveratrol Analogues
WO2006045096A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
AU2006275514B2 (en) * 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007084857A2 (en) * 2006-01-13 2007-07-26 President And Fellows Of Harvard College Methods and compositions for treating cell proliferative disorders
US8980954B2 (en) * 2006-04-25 2015-03-17 Stc.Unm Substituted cis- and trans-stilbenes as therapeutic agents
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
EP2170338A2 (en) * 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs modulates energy regulation and brain function
FI125590B (en) 2008-04-10 2015-12-15 Neste Oyj A process for the preparation of a composition for the preparation of pinosylvine and its compounds, a composition for the preparation of stilbene compounds, a process for the recovery of stilbene compounds, and fatty acid and resin acid esters of pinosylvine and its monomethyl ether
CA2711103C (en) 2008-06-26 2016-08-09 Resverlogix Corp. Methods of preparing quinazolinone derivatives
WO2010046926A2 (en) * 2008-10-17 2010-04-29 Aptuit Laurus Pvt Ltd Novel stilbene analogs
EP2382194B1 (en) 2009-01-08 2014-03-12 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US20100204340A1 (en) * 2009-02-09 2010-08-12 Muhammed Majeed Orally bioavailable stilbenoids- compositions and therapeutic applications thereof
US9050284B2 (en) * 2009-02-09 2015-06-09 Sami Labs Limited Orally bioavailable stilbenoids—compositions and therapeutic applications thereof
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
CN101531571B (zh) * 2009-04-17 2013-03-20 河北科技大学 六次甲基四胺氧化合成二苯乙烯类化合物的方法
KR101892987B1 (ko) 2009-04-22 2018-08-30 리스버로직스 코퍼레이션 신규한 소염제
CN101543477B (zh) * 2009-05-06 2011-01-19 河北科技大学 壳聚糖包覆3,5-二羟基-4-异丙基二苯乙烯的缓释微球及其制备方法
CN101564538B (zh) * 2009-06-08 2011-12-07 河北科技大学 3，5-二羟基-4-异丙基二苯乙烯-丁二酸酐-聚乙二醇复合物及其合成方法
CN101564537B (zh) * 2009-06-08 2011-05-25 河北科技大学 3，5-二羟基-4-异丙基二苯乙烯-溴乙酸乙酯-聚乙二醇复合物及其合成方法
DK2773354T3 (da) 2011-11-01 2019-08-05 Resverlogix Corp Oralformuleringer med øjeblikkelig frigivelse for substituerede quinazolinoner
CN102579322B (zh) * 2012-03-29 2013-10-23 河北科技大学 一种外用水凝胶剂及其制备方法与它的用途
CN102657602B (zh) * 2012-05-22 2013-08-07 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯壳聚糖凝胶剂及其制备方法
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
AU2015358910B2 (en) 2014-12-12 2019-01-24 Dermavant Sciences GmbH Novel method of use
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
US10195160B2 (en) * 2015-05-21 2019-02-05 Dermavant Sciences GmbH Topical pharmaceutical compositions
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
CN106467502A (zh) * 2015-08-21 2017-03-01 南京理工大学 2,3-二芳基环氧乙烷化合物及其制备方法
US9725406B1 (en) * 2016-10-13 2017-08-08 Resolvex Pharmaceuticals Inc. Substituted hydroxystilbenes and their therapeutic applications
WO2019094934A1 (en) 2017-11-10 2019-05-16 Dermavant Sciences GmbH Process for preparing tapinarof
KR102233566B1 (ko) * 2018-05-04 2021-03-30 서울대학교산학협력단 스틸벤 유도체를 포함하는 만성 폐질환의 예방 또는 치료용 조성물
US11497718B2 (en) * 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
CN114206315A (zh) * 2019-07-24 2022-03-18 索尔-格尔科技有限公司 用局部他匹那洛夫-egfr抑制剂组合物治疗皮肤病
WO2021236709A1 (en) 2020-05-19 2021-11-25 Teva Pharmaceuticals International Gmbh Solid state forms of tapinarof
CN113735693B (zh) * 2021-10-20 2023-07-14 河北维达康生物科技有限公司 一种白藜芦醇三甲醚的合成方法
CN116350609A (zh) * 2021-12-28 2023-06-30 上海泽德曼医药科技有限公司 用于抑制血管内皮生长的化合物及其用途
CN117003620A (zh) * 2022-05-07 2023-11-07 南京济群医药科技股份有限公司 作为AhR激动剂的二苯乙烯衍生物及其用途
CN115557963A (zh) * 2022-06-13 2023-01-03 大连大学 一类具有抗炎活性的聚酮类化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5111748A (en) * 1974-07-16 1976-01-30 Taisho Pharmaceutical Co Ltd Suchirubenjudotaino seizoho
JPS58159410A (ja) * 1982-03-18 1983-09-21 Mitsubishi Chem Ind Ltd 抗炎症剤
JPS6122046A (ja) * 1984-07-07 1986-01-30 Koichi Shiyudo スチルベン誘導体
DE3580134D1 (de) * 1984-07-07 1990-11-22 Shudo Koichi Prof Dr Chem Benzoesaeurederivate.
LU85558A1 (fr) * 1984-09-28 1986-04-03 Oreal Nouveaux derives naphtaleniques a action retinoique,leurs procedes de preparation et compositions medicamenteuse et cosmetique les contenant
US4788304A (en) * 1987-12-07 1988-11-29 American Home Products Corporation Phospholipase A2 inhibitors
US4933365A (en) * 1989-01-25 1990-06-12 American Home Products Corporation Phospholipase A2 inhibitors
GB9106177D0 (en) * 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
FR2676052B1 (fr) * 1991-05-02 1994-04-29 Cird Galderma Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique.
GB9204945D0 (en) * 1992-03-06 1992-04-22 Erba Carlo Spa 3-aryl-glycidic ester derivatives and process for their preparation
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
JPH0753359A (ja) * 1993-06-11 1995-02-28 Kao Corp リポキシゲナーゼ阻害剤
US5556996A (en) * 1994-12-29 1996-09-17 Allergan Oxiranyls disubstituted with a phenyl group and a substituted chromanyl or tetrahydroquinolinyl group having retinoid like activity
JPH08337523A (ja) * 1995-06-14 1996-12-24 Taiho Yakuhin Kogyo Kk 血管新生阻害剤
US6008260A (en) * 1998-01-09 1999-12-28 Pharmascience Cancer chemopreventative composition and method
AU2173899A (en) * 1998-02-06 1999-08-23 De Montfort University Hydroxylation activated prodrugs
AU4084599A (en) * 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
FR2785284B1 (fr) * 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d

Also Published As

Publication number Publication date
ES2334635T3 (es) 2010-03-15
CA2393297C (en) 2010-10-05
WO2001042231A2 (en) 2001-06-14
KR20020070310A (ko) 2002-09-05
EP1248774A2 (en) 2002-10-16
CA2393297A1 (en) 2001-06-14
WO2001042231A3 (en) 2001-11-01
CN1319959C (zh) 2007-06-06
DE60043120D1 (de) 2009-11-19
JP4880847B2 (ja) 2012-02-22
CN1407978A (zh) 2003-04-02
KR100805907B1 (ko) 2008-02-21
ATE444960T1 (de) 2009-10-15
AU780700B2 (en) 2005-04-14
EP1248774B1 (en) 2009-10-07
US20030171429A1 (en) 2003-09-11
AU2133001A (en) 2001-06-18
JP2003516400A (ja) 2003-05-13

Similar Documents

Publication Publication Date Title
HK1051691A1 (en) Hydroxylstilbenes and stilbene derivatives and analogues of anti-inflammatory and psoriasis treatment and protein kinase inhibition
NZ319090A (en) (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
BG105880A (en) Compounds useful as anti-inflammatory agents
NO20032254D0 (no) Forbindelser for inhibering av ekspresjon av VACM-I
MY124122A (en) Heterocyclic derivatives
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
HK1021699A1 (en) Pentafluorobenzenesulfonamides and analogs.
MXPA02009590A (es) Compuestos de 2-alquiliden-19-norvitamina d y sus usos terapeuticos.
DK0805796T3 (da) Celleadhæsionsinhiberende forbindelser
ATE384068T1 (de) Thiazolo(4,5-d)pyrimidinverbindungen zur behandlung von rheumathoider arthritis
ZA9810735B (en) Novel benzenesulfonamide inhibitors of pde-iv and their therapeutic use
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
ITMI931649A1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
NZ332096A (en) Alpha-hydroxylic acid derivatives their production and use in treating conditions requiring endothelin inhibition
MXPA02006610A (es) Sustancias para uso al tratar psoriasis.
NZ330944A (en) Peptide derivatives
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
HK1018265A1 (en) Piperazino derivatives as neurokinin antagonists
MX9708416A (es) Derivados de piperazino como antagonistas de neuroquininas.
EE200100125A (et) TAN-1057 derivaadid
IL113940A (en) Synthetic peptides which are elastase inhibitors and pharmaceutical compositions for the treatment of neutrophil associated inflammatory disease containing said inhibitors
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
BR9911151A (pt) Inibidores do fator de transcrição nf-kb
ES2189165T3 (es) Nuevos compuestos macrociclicos como inhibidores de metaloproteasa.
TR200200278T2 (tr) Kalsilitik bileşimler

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20201205